Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Lessons learned from Lykos’ FDA blowback. Our podcast began by recalling our podcast with Drysdale about one year ago.</li><li>At that time, the regulatory pathway for psychedelics was shrouded by uncertainty over the FDA’s concerns over the conduct of Lykos’ Phase 3 trial for its promising MDMA-AT for PTSD.</li><li>Drysdale explained how these revelations represented perfect timing for Cybin, right ahead of a pre-planned meeting with the FDA to prepare CYB003’s transition into its Phase 3 program.</li></ul>

Lessons learned from Lykos’ FDA blowback. Our podcast began by recalling our podcast with Drysdale about one year ago.At that time, the regulatory pathway for psychedelics was shrouded by uncertainty over the FDA’s concerns over the conduct of Lykos’ Phase 3 trial for its promising MDMA-AT for PTSD.Drysdale explained how these revelations represented perfect timing for Cybin, right ahead of a pre-planned meeting with the FDA to prepare CYB003’s transition into its Phase 3 program.

Cybin, Inc. -  CYB003 Vs. Other Aspiring Novel Depression Treatments